Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999
Quantitative MRI in Patients with Clinically Isolated Syndromes Suggestive of Demyelination
Neurol 52:599-606, Sailer,M.,et al, 1999
Utilization of Unconventional Treatments by Persons with MS:Is It Alternative or Complementary?
Neurol 52:626-629, Schwartz,C.E.,et al, 1999
Multiple Sclerosis Associated with Uveitis in Two Large Clinic-Based Series
Neurol 52:179-181, Biousse,V.,et al, 1999
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Magnetization Transfer Imaging of Patients with Definite MS and Negative Conventional MRI
Neurol 52:845-848, Filippi,M.,et al, 1999
Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999
Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis,Relation to Inflammatory Activity
Arch Neurol 56:345-351, van Walderveen,M.A.A.,et al, 1999
Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999
Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999
Quantitative MRI in CADASIL, Correlation with Disability and Cognitive Performance
Neurol 52:1361-1367, Dichgans,M.,et al, 1999
Fibromyalgia Syndrome a Decade Later
Arch Int Med 159:777-785, Goldenberg,D.L., 1999
Burden of Migraine in the United States, Disability and Economic Costs
Arch Int Med 159:813-818, Hu,X.H.,et al, 1999
Changes in Resource Use and Outcomes for Patients with Migraine Treated with Sumatriptan, A Managed Care Perspective
Arch Int Med 159:857-863, Lofland,J.H.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Brain Structure and Neurocognitive and Behavioural Function in Adolescents Who Were Born Very Preterm
Lancet 353:1653-1657, Stewart,A.L.,et al, 1999
Relevance of Hypointense Lesions on Fast Fluid-Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis
AJNR 20:813-820, Rovaris,M.,et al, 1999
The Relationship of MS to Physical Trauma and Psychological Stress, Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 52:1737-1745, Goodin,D.S.,et al, 1999
Trigeminal Neuralgia Triggered by Auditory Stimuli in Multiple Sclerosis
Arch Neurol 56:731-733, Hartmann,M.,et al, 1999
Ibuprofen Treatment Versus Gradual Introduction of Interferon B-1b in patients with MS
Neurol 52:1893-1895, Rice,G.P.A.,et al, 1999
Cavernous Haemangioma Mimicking Multiple Sclerosis
BMJ 318:1604-1605, Cader,M.Z.&Winer,J.B., 1999
Cerebrospinal Fluid Findings in CADASIL
Neurol 53:233, Dichgans,M.,et al, 1999
Lamotrigine Adjunctive Therapy in painful Phenomena in MS:Preliminary Observations
Neurol 53:433, Cianchetti,C.,et al, 1999
Encephalitis after Hepatitis B Vaccination, Recurrent Disseminated Encephalitis or MS?
Neurol 53:396-401, Tourbah,A.,et al, 1999
Multiple Sclerosis in Children Under 6 Years of Age
Neurol 53:478-484, Ruggieri,M.,et al, 1999
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Magnetic Resonance Imaging Results of the PRISMS Trial:A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-B1a in Relapsing-Remitting Multiple Scleroosis
Ann Neurol 46:197-206, Li,D.K.B.,et al, 1999
Chronic Thalamic Stimulation for the Tremor of Multiple Sclerosis
Neurol 53:625-628, Montgomery,E.B.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Chlamydia Pneumoniae Infection of the Central Nervous System in Multiple Sclerosis
Ann Neurol 46:6-14,4, Sriram,S.,et al, 1999
A Longitudinal Study of Brain Atrophy in Relapsing Multiple Sclerosis
Neurol 53:139-148, Simon,J.H.,et al, 1999
The Contribution of Magnetic Resonance Imaging to the Diagnosis of Multiple Sclerosis
Neurol 53:448-456, Fazekas,F.,et al, 1999
Optic Neuritis as Onset Manifestations of Multiple Sclerosis
Neurol 53:473-478, Sorensen,T.L.,et al, 1999
Association of MS with Thyroid Disorders
Neurol 53:883-885, Karni,A.&Abramsky,O., 1999
Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999
Olfactory Dysfunction in Multiple Sclerosis:Relation to Longitudinal Changes in Plaque Numbers in Central Olfactory Structures
Neurol 53:880-882, Doty,R.L.,et al, 1999
Isolated Trochlear Nerve Palsy in Patients with Multiple Sclerosis
Neurol 53:877-879, Jacobson,D.M.,et al, 1999
Multiple Sclerosis That is Progressive From the Time of Onset, Clinical Characteristics and Progression of Disability
Arch Neurol 56:1138-1142, Andersson,P.B.,et al, 1999
The Clinical Course of Neuromyelitis Optica (Devic's Syndrome)
Neurol 53:1107-1114, Wingerchuk,D.M.,et al, 1999
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Rehabilitation of Persons With Traumatic Brain Injury
JAMA 282:974-983,989, NIH Consensus Development Panel on Rehab with TBI, 1999
Musculoskeletal and Neurologic Outcomes in Patients with Previously Treated Lyme Disease
Ann Int Med 131:919-926, Shadick,N.A.,et al, 1999
Treatment Recommendations for Interferon-B in Multiple Sclerosis
JNNP 67:561-566, Polman,C.H.,et al, 1999
General Neurologist and Subspecialist Care for Multiple Sclerosis, Patients' Perceptions
Neurol 53:1190-1197, Vickrey,B.G.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Suppression of Pendular Nystagmus by Smoking Cannabis in a Patient with Multiple Sclerosis
Neurol 53:2209-2210, Schon,F.,et al, 1999